Abstract:

Objective To investigate the clinical features and efficacy of 131I remnant ablation of differentiated thyroid carcinoma complicated with hyperthyroidism. Methods The clinical data of 1 233 patients with DTC hospitalized between January 2000 and December 2009 were retrospectively analysed, among whom 13 had history of hyperthyroidism. Thyroxine tablets administration withdrew before admission, and iodine-free diet was carried out for 3 to 6 weeks. Before ¹³¹I treatment, serum thyroglobulin, thyroglobulin antibodies, thyroid hormones (TT3, TT4, FT3, FT4), thyroid stimulating hormone （TSH）, blood routine, liver and renal function were examined, and the disease condition was evaluated by neck ultrasound. Four to 6 months after 131I treatment, all patients were followed up for the treatment efficacy. Results The positive rate of thyroid ultrasonography for DTC complicated with hyperthyroidism was 61.54% （8/13）, and those of thyroid scintigraphy and fine needle aspiration biopsy were 33.33% （2/6）and 75.00% (3/4) respectively. The total dose of 131I used for DTC complicated with hyperthyroidism was significantly lower than that for DTC （P<0.05）. Four to six months after 131I remnant ablation, 11of the 13 patients (84.26%) had successful ablation of residual thyroid tissues after first administration of ¹³¹I, which was significantly higher than that of patients with single DTC (55.90%). Conclusion Thyroid ultrasonography, thyroid scintigraphy and fine needle aspiration biopsy remain important means in examining patients with DTC complicated with hyperthyroidism. ¹³¹I treatment for ablation of residual thyroid tissues in patients with DTC complicated with hyperthyroidism may yield better efficacy than in patients with single DTC.

Key words: thyroid carcinoma, primary hyperthyroidism, ¹³¹I